Cipmolnu 200 Capsule Molnupiravir 200mg

Product Descriptions

Cipmolnu 200 Capsule is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021. Cipmolnu 200 Capsule is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use. Cipmolnu 200 Capsule should be taken orally for no longer than 5 consecutive days. It is important to complete the entire 5 days of treatment, therefore do not stop taking it even if you feel better. The medicine may cause dizziness, headache, diarrhea, and nausea in some patients. If one experiences any such side effects, discuss them with the doctor. They may help with the treatment or suggest ways to prevent them. Before taking Cipmolnu 200 Capsule, let the doctor know if you have any pre-existing medical conditions. To make sure it is safe for you, inform your doctor about all the other medications you are taking. The use of Cipmolnu 200 Capsule is not recommended in pregnant women. Pregnant and breastfeeding women should consult with their doctors before taking this medicine.